New Treatments & Clinical Trials for Follicular Lymphoma

Follicular lymphoma is a slow-growing blood cancer that starts in white blood cells called B cells. It's the second most common type of non-Hodgkin lymphoma. Many people live for years with the disease, which can be managed with cycles of treatment and observation rather than continuous therapy.

What's actually going on in research

Trials are testing combinations of targeted drugs that avoid traditional chemotherapy, newer antibody drugs that last longer in the body, CAR T-cell therapy for relapsed disease, and bispecific antibodies that redirect the immune system. Researchers are also studying whether early treatment changes outcomes compared to watchful waiting for low-burden disease.

What to know before you search

Eligibility typically depends on disease stage, number of prior treatments, whether the lymphoma is causing symptoms, and sometimes genetic features of the tumor cells.

What types of trials are currently open

• Treatment trials — Testing new drug combinations, often comparing chemotherapy-free regimens to standard approaches for newly diagnosed disease.
• Relapsed disease trials — Testing CAR T-cell therapy, bispecific antibodies, and novel targeted drugs for lymphoma that has returned after prior treatment.
• Maintenance therapy trials — Testing whether drugs given after initial treatment can delay the lymphoma's return.
• Watchful waiting studies — Following people with low-burden disease to understand when treatment becomes necessary and what predicts progression.
• Biomarker studies — Analyzing tumor samples and blood tests to identify which patients are likely to respond to specific treatments or have more aggressive disease.